Sample size determination in clinical trials with multiple co-primary binary endpoints

被引:46
|
作者
Sozu, Takashi [1 ,2 ]
Sugimoto, Tomoyuki [2 ]
Hamasaki, Toshimitsu [1 ,2 ]
机构
[1] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Biomed Stat, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
correlated endpoints; multivariate Bernoulli; association measures; continuity correction; arcsine transformation; Fisher's exact method; EFFICACY; DESIGN; ISSUES; POWER;
D O I
10.1002/sim.3972
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:2169 / 2179
页数:11
相关论文
共 50 条
  • [41] Method of balanced adjustment in testing co-primary endpoints
    Kordzakhia, George
    Siddiqui, Ohidul
    Huque, Mohammad F.
    STATISTICS IN MEDICINE, 2010, 29 (19) : 2055 - 2066
  • [42] Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints
    Sinha, Arup K.
    Moye, Lemuel, III
    Piller, Linda B.
    Yamal, Jose-Miguel
    Barcenas, Carlos H.
    Lin, Jianchang
    Davis, Barry R.
    STATISTICS IN MEDICINE, 2019, 38 (21) : 3985 - 3996
  • [43] A two-stage design with two co-primary endpoints
    Song, James X.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2015, 1 : 2 - 4
  • [44] Blinded sample size reestimation in non-inferiority trials with binary Endpoints
    Friede, Tim
    Mitchell, Charles
    Mueller-Velten, Guenther
    BIOMETRICAL JOURNAL, 2007, 49 (06) : 903 - 916
  • [45] Sample size calculations for paediatric multiple sclerosis clinical trials using clinical relapse and MRI lesion endpoints
    Verhey, L. H.
    Signori, A.
    Arnold, D. L.
    Bar-Or, A.
    Sadovnick, A. D.
    Marrie, R. A.
    Banwell, B.
    Sormani, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 92 - 92
  • [46] Multiple co-primary endpoints: Medical and statistical solutions - A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America
    Offen, Walter
    Chuang-Stein, Christy
    Dmitrienko, Alex
    Littman, Gary
    Maca, Jeff
    Meyerson, Laura
    Muirhead, Robb
    Stryszak, Paul
    Boddy, Alex
    Chen, Kun
    Copley-Merriman, Kati
    Dere, Willard
    Givens, Sam
    Hall, David
    Henry, David
    Jackson, Joseph D.
    Krishen, Alok
    Liu, Thomas
    Ryder, Steve
    Sankoh, A. J.
    Wang, Julia
    Yeh, Chyon-Hwa
    DRUG INFORMATION JOURNAL, 2007, 41 (01): : 31 - 46
  • [47] Optimal Two-Stage Design for the Phase II Cancer Clinical Trials With Responses and Early Progression as Co-primary Endpoints
    Tan, Xianming
    Takahara, Glen
    Tu, Dongsheng
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (03): : 348 - 354
  • [48] Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America
    Walter Offen
    Christy Chuang-Stein
    Alex Dmitrienko
    Gary Littman
    Jeff Maca
    Laura Meyerson
    Robb Muirhead
    Paul Stryszak
    Alex Baddy
    Kun Chen
    Kati Copley-Merriman
    Willard Dere
    Sam Givens
    David Hall
    David Henry
    Joseph D. Jackson
    Alok Krishen
    Thomas Liu
    Steve Ryder
    A. J. Sankoh
    Julia Wang
    Chyon-Hwa Yeh
    Drug information journal : DIJ / Drug Information Association, 2007, 41 : 31 - 46
  • [49] Power and sample size considerations in clinical trials with competing risk endpoints
    Maki, Ellen
    PHARMACEUTICAL STATISTICS, 2006, 5 (03) : 159 - 171
  • [50] Sample size determination in complex clinical trials comparing more than two groups for survival endpoints
    Ahnn, S
    Anderson, SJ
    STATISTICS IN MEDICINE, 1998, 17 (21) : 2525 - 2534